Abstract:
OBJECTIVE:In China, Hib vaccine is a private-sector vaccine that is an option for parents to select to give to their children; it must be paid for out-of-pocket because it is not included in the government's Expanded Program on Immunization (EPI). We evaluated utilization patterns of Hib vaccine to provide evidence in support of development of a national Hib vaccination strategy. METHODS:We obtained lists of children from immunization information systems (IIS) of counties or districts in 8 provinces of China. Using these lists, we selected 10 children at random from each birth cohort from 2008 through 2012. We obtained Hib vaccination dates from official vaccination certificates. The target sample size was 1,000 children. RESULTS:We were able to obtain records for 978 subjects of the selected subjects; of these, 44.79% had received at least 1 dose of Hib vaccine, and 15.54%, 5.83%, 12.27%, and 11.15% had received one, two, three, and four doses, respectively. Per capita GDP was positively correlated with receipt of at least one dose of Hib vaccine. Among the 438 subjects who received Hib vaccine, 27% received 1 dose after 12 months of age; 15%, 7%, and 23% received one of three other patterns of Hib vaccination recommended by the World Health Organization (WHO) [a 3-dose primary series; 2 primary series doses and 1 booster; or 3 primary series doses and 1 booster]. The other 28% of subjects received patterns of Hib vaccination not recommended by WHO. Considering protection from Hib disease as receipt of a WHO-recommended Hib vaccine schedule, 29% of subjects could be considered protected after 12 months of age, 52% could be considered protected during infancy and beyond, and 19% could be considered to not have been protected adequately, despite being vaccinated. CONCLUSIONS:Coverage with Hib vaccine was low. There were significant differences between WHO recommendations and actual patterns of use of Hib vaccine, with half of vaccine recipients receiving no protection during infancy and one fifth receiving non-protective Hib vaccination patterns. Inclusion of Hib vaccine into China's EPI system, which provides vaccine at no charge to parents and makes specific vaccination schedule standards, has potential to make more effective use of Hib vaccine.
journal_name
Hum Vaccin Immunotherjournal_title
Human vaccines & immunotherapeuticsauthors
Li Y,Yue C,Wang Y,Zhu X,Martin K,Scherpbier RW,Liu J,Wang Z,Ma Y,Cheng H,Zhang Z,Wang Q,Li H,Xie S,Xiao Q,Wang H,An Zdoi
10.1080/21645515.2017.1420447subject
Has Abstractpub_date
2018-04-03 00:00:00pages
894-899issue
4eissn
2164-5515issn
2164-554Xjournal_volume
14pub_type
杂志文章abstract::Resurgent mumps outbreaks have raised questions about the current efficacy of mumps vaccines. We have applied immunoinformatics techniques based on principal component analysis to evaluate patterns in predicted B-cell linear epitopes, MHC binding affinity and cathepsin cleavage in the hemagglutinin neuraminidase prote...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.4161/hv.27139
更新日期:2014-01-01 00:00:00
abstract::Typhax is an investigational typhoid fever vaccine candidate that was GMP manufactured applying Protein Capsular Matrix Vaccine (PCMV) technology. It consists of Vi polysaccharide antigen, derived from S. Typhi, non-covalently entrapped in a glutaraldehyde catalyzed cross-linked α-poly-L-lysine and CRM197 protein matr...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2019.1599674
更新日期:2019-01-01 00:00:00
abstract::Disseminated bacillus Calmette-Guérin (BCG) disease is a rare and serious adverse event following immunization (AEFI) with BCG. Here, we reported two cases of disseminated BCG disease in the same family and reviewed the literature to identify another 35 cases in China. The average age at onset was 3.7 ± 2.1 months amo...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2020.1819102
更新日期:2020-10-20 00:00:00
abstract::Although immunotherapies have been employed for many decades, immune checkpoint inhibitors have only recently entered the oncologic landscape. Avelumab is a fully human monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby inhibiting immunosuppression in the tumor mi...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/21645515.2018.1551671
更新日期:2019-01-01 00:00:00
abstract::Dengue is prevalent in the Asia-Pacific region. Participants of two immunogenicity and safety phase II studies conducted in Singapore and Vietnam (NCT0088089 and NCT00875524, respectively) were followed for up to four years after third vaccine dose of a recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TD...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章,随机对照试验
doi:10.1080/21645515.2019.1578595
更新日期:2019-01-01 00:00:00
abstract:BACKGROUND:Health authorities recommend influenza vaccination to diabetic patients. Nevertheless, the vaccination coverage of adults was low in China. This study aimed to estimate influenza vaccination intentions and actual uptake among diabetic patients in China and identify the motivators and barriers associated with...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2020.1761201
更新日期:2020-05-27 00:00:00
abstract::Anflu® is a seasonal trivalent inactivated split-virion influenza vaccine manufactured by Sinovac Biotech Co., Ltd. The objectives of this study were to evaluate the safety of Anflu® (2013-14 formulation: H1N1, H3N2 and BYAM) in infants and adults and its immunogenicity and cross-reactivity against mismatched influenz...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2015.1123357
更新日期:2016-05-03 00:00:00
abstract::Group A rotavirus (RV-A) genotypes isolated in Malaysia was studied to estimate the effectiveness of a universal RV-A vaccination in Malaysia. A simple mathematical model was used, with input from a two-year, two-center, prospective study on hospitalization of RV-A gastroenteritis (RVGE) in young children, published d...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.4161/hv.21577
更新日期:2012-10-01 00:00:00
abstract::The 13-valent pneumococcal conjugated vaccine (PCV13) is already recommended for some adult groups and is being considered for wider use in many countries. In order to identify the strengths and limitations of the existing economic evaluation studies of PCV13 in adults and the elderly a literature review was conducted...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章,评审
doi:10.1080/21645515.2015.1011954
更新日期:2015-01-01 00:00:00
abstract::Although genital HPV is the most prevalent STI in the US, rates of vaccination uptake among high-risk subgroups remain low. Investigations of vaccine compliance have mainly targeted mother-daughter dyads, which in some settings may prove difficult. This study examines an innovative culturally tailored, computer-delive...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章,随机对照试验
doi:10.1080/21645515.2015.1070996
更新日期:2015-01-01 00:00:00
abstract::Varicella zoster virus (VZV) is primarily known for causing varicella in childhood, but can reactivate again as herpes zoster (HZ) after a period of latency, mainly in persons older than 50 years. Universal varicella vaccination was introduced in Germany in 2004, while HZ vaccination has not been recommended yet. We a...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2015.1135279
更新日期:2016-07-02 00:00:00
abstract::Better adjuvants are needed for vaccines against seasonal influenza. TLR7 agonists are potent activators of innate immune responses and thereby may be promising adjuvants. Among the imidazoquinoline compounds, 1-benzyl-2-butyl-1H-imidazo[4,5-c]quinolin-4-amine (BBIQ) was reported to be a highly active TLR7 agonist but...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2019.1710409
更新日期:2020-08-02 00:00:00
abstract::Cancer immunotherapy has seen a tremendous number of failures and only few recent regulatory successes. This review is a first in a series dedicated to evaluate the status of current global clinical pipeline for cancer vaccines. Apart from specific areas of medical need which can be addressed by cancer vaccines, the a...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章,评审
doi:10.4161/hv.20474
更新日期:2012-08-01 00:00:00
abstract::Immunization can contribute to a dramatic reduction in number of vaccine-preventable diseases among children. The aim of this study is to investigate mothers' awareness about child vaccines and vaccination in Jordan. This study was a community-based, cross-sectional study that was performed at public places in Irbid C...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.4161/hv.28608
更新日期:2014-01-01 00:00:00
abstract::Japanese encephalitis virus is the major cause of encephalitis in India. To control the increasing incidence and fatal outbreaks, SA 14-14-2 vaccine was introduced initially in 104 endemic districts in phased manner from 2006 to 2011. As there is no data available before 2008 on the number of Japanese encephalitis (JE...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2018.1564435
更新日期:2019-01-01 00:00:00
abstract::DC-based therapeutic vaccines as a promising strategy against chronic infections and cancer have been validated in several clinical trials. However, DC-based vaccines are complex and require many in vitro manipulations, which makes this a personalized and expensive therapeutic approach. In contrast, DNA-based vaccines...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2015.1020265
更新日期:2015-01-01 00:00:00
abstract::A new live attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) has been developed based on innovative technology to give protection against JE with an improved immunogenicity and safety profile. In this phase 3, observer-blind study, 274 children aged 12-24 months were randomized 1:1 to receive one dose of...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.4161/hv.29743
更新日期:2014-01-01 00:00:00
abstract::Variations of post-translational modifications are important for stability and in vivo behavior of therapeutic antibodies. A recombinant humanized anti-cocaine monoclonal antibody (h2E2) was characterized for heterogeneity of N-linked glycosylation and disulfide bonds. In addition, charge heterogeneity, which is parti...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.4161/21645515.2014.990856
更新日期:2015-01-01 00:00:00
abstract::Italy was one of the first countries in the world to introduce a routine vaccination program against HBV for newborns and 12-y-old children. From a clinical point of view, such strategy was clearly successful. The objective of our study was to verify whether, at 20 y from its implementation, hepatitis B universal vacc...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.4161/hv.23827
更新日期:2013-05-01 00:00:00
abstract::Purpose: Gaps remain in the public's knowledge of the human papillomavirus (HPV). We assessed racial/ethnic and gender disparities in knowledge and awareness of HPV and the HPV vaccine among US adults. METHODS:Data from the Health Information National Trends Survey 4 Cycle 3 (September - December 2013) and Cycle 4 (A...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2017.1363133
更新日期:2017-11-02 00:00:00
abstract::One of the main challenges in early clinical research with respiratory syncytial virus (RSV) live-attenuated vaccines (LAVs) is to assess immunogenicity in healthy adults. Healthy adults will have preexisting levels of serum neutralizing antibodies that could prematurely neutralize the LAV and underestimate the potent...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2019.1688040
更新日期:2020-06-02 00:00:00
abstract::This review aims to present the unique considerations for manufacturing and the regulation of new vaccines in Muslim-populated countries such as Malaysia. Our specific objectives are to highlight vaccine production and the ingredients of concern, summarize the current mechanism for ruling and recommendations on new va...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2019.1667206
更新日期:2020-03-03 00:00:00
abstract::In Japan, government support for human papillomavirus (HPV) vaccination began in November 2010. However, the mass media repeatedly reported on severe adverse events. The Japanese Ministry of Health, Labor and Welfare suspended proactive recommendations for HPV vaccines in June 2013. Japan's HPV vaccination rate droppe...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2020.1817715
更新日期:2020-10-29 00:00:00
abstract::We investigated the relationship between reported cases of influenza in Catalonia (Spain). Covariates analyzed were: population, age, data of report of influenza, and health region during 2010-2014 using data obtained from the SISAP program (Institut Catala de la Salut - Generalitat of Catalonia). Reported cases were ...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.4161/hv.36168
更新日期:2015-01-01 00:00:00
abstract::There is currently a lack of sufficient data on human papillomavirus (HPV)-attributable cervical carcinoma in China. Accordingly, we aimed to determine the prevalence and genotype distribution of HPV among women with cervical lesions in Shenzhen, in order to evaluate the potential benefit of HPV vaccination programs a...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2020.1805993
更新日期:2020-09-22 00:00:00
abstract::A previous phase 3, randomized, multicenter study showed the immunogenicity of a primary vaccination of subjects aged 11 to 17 years with the quadrivalent meningococcal vaccine conjugated to tetanus toxoid (MenACWY-TT) or the quadrivalent meningococcal polysaccharide vaccine (MenACWY-PS). This extension study evaluate...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2020.1744363
更新日期:2020-06-02 00:00:00
abstract:OBJECTIVE:To evaluate the incidence of adverse events following administration of an Inactivated poliomyelitis vaccine (IPV) manufactured by Serum Institute of India Pvt. Ltd., Pune, India. METHODS:A single 0.5 ml dose of the IPV was administered intramuscularly to children attending private clinics or out-patient dep...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2017.1356960
更新日期:2017-11-02 00:00:00
abstract::Objective: The objective of this study was to analyze the 100 most cited studies on vaccine.Methods: A comprehensive search of studies on vaccine was performed in the Web of Science Core Collection without year or language restrictions. The 100 top-cited studies were retrieved after screening abstracts or full-texts. ...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2019.1614398
更新日期:2019-01-01 00:00:00
abstract::The present study evaluated the safety and immunogenicity of the 2013/2014 trivalent surface antigen inactivated subunit seasonal influenza virus vaccine Fluvirin® in healthy adults (18 - ≤ 60 years) and elderly (>60 years). The vaccine contained 15 µg haemagglutinin protein from each of influenza A/California/7/2009 ...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2015.1064570
更新日期:2015-01-01 00:00:00
abstract::Nationally, human papillomavirus (HPV) vaccination rates fall short of the Healthy People 2020 goal of 80% completion. Although strategies to increase these rates exist, low rates persist. We used concept mapping with state-level stakeholders to better understand barriers and facilitators to HPV vaccination. Concept m...
journal_title:Human vaccines & immunotherapeutics
pub_type: 杂志文章
doi:10.1080/21645515.2020.1839290
更新日期:2020-12-17 00:00:00